Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

Clinical trial NCT06382948 · RECRUITING

Trial details

NCT number: NCT06382948
Sponsor: MedSIR
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Advanced Breast Cancer ER-positive Breast Cancer HER2-negative Breast Cancer ESR1 Gene Mutation

Start date: 2024-12-05
Primary completion: 2027-09-01
Enrollment: 300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.